EP Patent

EP3250554A1 — A carboxamide derivative and its diastereomers in stable crystalline form

Assigned to Orion Oyj · Expires 2017-12-06 · 8y expired

What this patent protects

The present disclosure relates to solid crystalline forms of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I)and th…

USPTO Abstract

The present disclosure relates to solid crystalline forms of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I)and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.

Drugs covered by this patent

Patent Metadata

Patent number
EP3250554A1
Jurisdiction
EP
Classification
—
Expires
2017-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.